Second Alzheimer's Drug Donanemab Faces NHS Use Block

The Alzheimer's drug Donanemab is expected to face a block for its use within the NHS, according to a report by The Telegraph. This marks the second time such a drug has faced obstacles within the UK healthcare system.

The Alzheimer's drug Donanemab is expected to face restrictions from National Health Service (NHS) usage, The Telegraph reports.

This development follows a series of similar barriers faced by Alzheimer's treatments within the UK healthcare framework.

The decision is likely to spark debates about drug accessibility and NHS policy parameters.

(With inputs from agencies.)